InterVene is a trailblazing medical device company focused on reshaping the landscape of treating chronic post-thrombotic venous occlusions and obstructions – the severe late term complications arising from deep vein thrombosis and chronic venous insufficiency.
Neuspera Medical, Inc. is committed to developing implantable medical device technology that will improve the lives of patients battling chronic illness. With the first intended indication for use as Urinary Urge Incontinence (UUI), the platform technology is ultimately designed to deliver targeted bioelectronic medicine for a variety of conditions. Neuspera’s minimally-invasive implants with external wearable transmitters offer the possibility for therapies to reach deeper, harder to access anatomical locations in the body.
CVRx® is a leader in innovative technologies that address the unmet needs in cardiovascular diseases with safe and effective therapies. CVRx technology harnesses and harmonizes the body’s natural systems to deliver effective cardiovascular therapies. CVRx’s Barostim device is the first ever medical device to receive the FDA’s Breakthrough Device designation.
NuXcel is a global medical device accelerator with a unique business model and locations in Ireland, Minneapolis, and Silicon Valley. NuXcel is led by medical device veterans who have brought multiple novel medical technologies to the market and helped create world class companies. ShiraTronics is the first spin off company from NuXcel.
Hyalex is developing a novel polymer technology, originally developed at Stanford University, that mimics the native cartilage in form and function, supporting a wide range of orthopedic applications.
NeoChord is a privately held medical technology company leading the advancement of mitral valve repair in patients suffering from mitral valve regurgitation.